Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma

The addition of Darzalex daratumumab to the standard treatment combination consisting of Velcade bortezomib melphalan and prednisone VMP reduces disease progression or death by 50 among patients with newly diagnosed multiple myeloma who are not eligible t [...]